Biotechnology

Biohaven Pharmaceutical

HC Wainwright Maintains Biohaven's Neutral Rating, Projects $1.25 EPS for 2029 Fiscal Year

UBS Analyst Maintains Hold Rating on Biohaven Ltd.

Biohaven Completes $175 Million Equity Issuance

BTIG Maintains Buy Rating on Biohaven Ltd.

Douglas Tsao Maintains Buy Rating on Biohaven Ltd.

Citigroup Maintains Buy Rating on Biohaven Ltd. with Reduced Price Target

US Bank Securities Reiterates Hold Rating on Biohaven Ltd.

Biohaven Pharmaceutical released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 343.83 K), actual EPS USD -1.6391 (forecast USD -1.9338)

Biohaven Pharmaceutical released FY2025 9 Months Earnings on November 10 (EST), with actual revenue of USD 0 and EPS of USD -5.7491

Biohaven Ltd. Announces Business Focus and Goals

Biohaven Ltd. Reports Q3 2025 Financials and Highlights Late-Stage Clinical Project Focus

H.C. Wainwright analyst reiterates buy rating for Biohaven

Samantha Sameneko Gives Biohaven Ltd a Buy Rating

Citi Analyst Assigns Buy Rating and Price Target to Biohaven

Biohaven Ltd. Updates Progress on NDA for SCA Treatment

Leerink Partners cuts Biohaven's target price to $50

Biohaven Pharmaceutical released FY2025 Semi-Annual Earnings on August 11 (EST), actual revenue USD 0, actual EPS USD -4.1095

Biohaven Pharmaceutical released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.9355 (forecast USD -1.8728)

Biohaven Inc Reports $198.147 Million Net Loss in Q2

Law Firm Partner Urges Biohaven Investors Suffering Losses to Contact

Treasure Gbl

SMX Security Matters

Wheeler Real Estate

Gulf Resources

DigitalBridge

Irobot

Toro

Lichen

Springview

Dreamland

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap